Heritable pulmonary arterial hypertension – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Heritable pulmonary arterial hypertension – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Sotatercept for Improving Heart Function in Patients with Pulmonary Arterial Hypertension https://clinicaltrials.eu/trial/study-on-sotatercept-for-improving-heart-function-in-patients-with-pulmonary-arterial-hypertension/ Wed, 29 Apr 2026 15:04:37 +0000 https://clinicaltrials.eu/trial/study-on-sotatercept-for-improving-heart-function-in-patients-with-pulmonary-arterial-hypertension/ This clinical trial is focused on studying the effects of a treatment for Pulmonary Arterial Hypertension (PAH), a condition where the blood pressure in the arteries of the lungs is higher than normal. The treatment being tested is called Sotatercept, also known by its code name ACE-011. Sotatercept is administered as a powder that is mixed into a solution and given through an injection under the skin.

The purpose of this study is to evaluate how Sotatercept affects the function of the right side of the heart in patients with PAH. The study will observe changes in how the heart works and how it interacts with the blood vessels in the lungs. Participants will receive Sotatercept over a period of 24 weeks, and various heart functions will be monitored to assess the treatment’s impact.

This study is designed to provide insights into how Sotatercept can help manage PAH by improving heart function. The trial is open-label, meaning both the researchers and participants know what treatment is being administered. The information gathered from this study aims to enhance understanding of PAH treatment and potentially improve outcomes for those affected by this condition.

]]> Study on Dapagliflozin for Patients with Pulmonary Arterial Hypertension to Improve Exercise Capacity and Heart Function https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-pulmonary-arterial-hypertension-to-improve-exercise-capacity-and-heart-function/ Wed, 29 Apr 2026 14:22:45 +0000 https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-pulmonary-arterial-hypertension-to-improve-exercise-capacity-and-heart-function/ This clinical trial is focused on studying the effects of the medication dapagliflozin, also known as Forxiga, in patients with a condition called Pulmonary Arterial Hypertension (PAH). PAH is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The study also includes patients with Chronic Thromboembolic Pulmonary Hypertension, which is a related condition. The purpose of the study is to evaluate how dapagliflozin affects exercise capacity and heart and lung function in patients who are already receiving other treatments for PAH.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last for about three months, during which participants will take the tablets by mouth. Throughout the study, various tests will be conducted to assess changes in exercise ability, heart and lung function, and other health indicators. These tests will help researchers understand the impact of dapagliflozin on the body.

The study aims to provide valuable information on whether dapagliflozin can improve the health and quality of life for people with PAH. By comparing the effects of the medication with the placebo, researchers hope to determine its effectiveness and safety in managing this challenging condition. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to gather accurate data on the medication’s effects.

]]>